Generated June 23, 2026 at 8:31 PM ET
· Covers June 23 trading day
· 10 of 227 ready 8-Ks selected
· AI-assisted overview
Today's filings featured several high-materiality restructuring and M&A events. Sangamo Therapeutics filed for Chapter 11 bankruptcy with stalking horse asset sales to Lilly and Astellas, while Office Properties Income Trust emerged from Chapter 11 after cancelling old shares and issuing new secured notes. In M&A, Boundless Bio agreed to merge with Serapha in a deal where Serapha holders will own ~96% of the combined company, Quantum Computing Inc. acquired NHanced Semiconductors for up to $145M, and Nuvectis Pharma in-licensed two clinical-stage compounds from Haisco. Regulatory news included DevvStream receiving a Nasdaq delisting determination and an appeal pending, Inmune Bio receiving UK regulatory alignment for its RDEB therapy, and Smith Micro regaining Nasdaq compliance. Enanta lost a Federal Circuit appeal invalidating a Paxlovid patent, and CS Diagnostics restated financials after a $499.4 million intangible asset error.
M&A
negative
materiality 0.90
June 23, 2026, 8:30 AM ET
Boundless Bio to merge with Serapha; Serapha equityholders to own ~96%
- Pre-merger Serapha equityholders to own ~96.31% of combined company; Boundless Bio holders ~3.69% on fully diluted basis.
- Serapha raises $138M Series A preferred and $92M PIPE concurrently with merger agreement.
- Boundless Bio to cut ~75% of workforce; expects $3M-$5M in termination costs, substantially completed in Q3 2026.
QUBT
Quantum Computing Inc.
M&A
positive
materiality 0.90
June 23, 2026, 8:55 AM ET
Quantum Computing Inc. acquires NHanced Semiconductors for $73.1M plus up to $72M earnout
- Purchase price $73.1M ($68.1M cash + ~$5M stock) plus earnout up to $72M based on 2027-2028 revenue/EBITDA thresholds.
- NHanced becomes wholly owned subsidiary; acquisition launches Fab 2 manufacturing facility years ahead of schedule.
- QCi adds nanophotonics fabrication, TFLN platform, advanced packaging, and engineering talent.
regulatory
negative
materiality 0.85
June 23, 2026, 4:16 PM ET
DevvStream receives Nasdaq delisting determination; trading suspended June 24, 2026
- Nasdaq Hearings Panel determined suspension due to bid price noncompliance (below $1.00) and failure to meet net income rule.
- Trading suspension at open on June 24, 2026; shares expected to trade on Pink Limited Market under symbol DEVS.
- Company intends to appeal to the Nasdaq Listing Council, but appeal does not stay suspension.
NVCT
Nuvectis Pharma, Inc.
M&A
positive
materiality 0.85
June 23, 2026, 7:00 AM ET
Nuvectis in-licenses ex-China rights to two clinical-stage compounds from Haisco for up to $1.46B
- Upfront and near-term payments total up to $40M; potential milestones up to $1.421B plus tiered royalties.
- NXP100 (CFBi) has two MAAs under review in China for PNH; Ph3 ongoing in IgAN; Ph2 in LN.
- NXP200 (paradox-breaker BRAFi) showed >40% response in gliomas and durable responses in multiple tumors; Phase 1b ongoing.
regulatory
positive
materiality 0.75
June 23, 2026, 4:05 PM ET
MHRA aligns with INmune Bio on regulatory path for Ebstrocel in RDEB; UK MAA planned in 2026
- MHRA minutes from May 12 pre-MAA meeting confirm agreement across CMC, non-clinical, and clinical evidence packages.
- Agency recognizes MissionEB Phase 2 data as demonstrating clinically meaningful symptomatic benefit in pain and pruritus.
- MHRA provided endpoint recommendations for confirmatory Phase 3, moving away from wound closure as primary focus.
ENTA
ENANTA PHARMACEUTICALS INC
litigation
negative
materiality 0.80
June 23, 2026, 5:28 PM ET
Enanta loses Federal Circuit appeal; Paxlovid patent claims invalidated
- Federal Circuit affirmed Dec 2024 summary judgment, ruling claims of U.S. Patent No. 11,358,953 invalid.
- Patent covered Pfizer's COVID-19 antiviral Paxlovid (nirmatrelvir; ritonavir).
- Enanta had sought damages for infringement; appeal loss eliminates potential royalty stream.
SMSI
SMITH MICRO SOFTWARE, INC.
regulatory
positive
materiality 0.65
June 23, 2026, 4:00 PM ET
Smith Micro regains Nasdaq minimum bid price compliance after stock closes above $1.00 for 10 days
- Company received Nasdaq notification on June 23, 2026 that it regained compliance with Minimum Bid Price Requirement.
- Stock closed at $1.00 or higher for 10 consecutive business days ending June 22, 2026.
- Nasdaq bid price deficiency matter is now closed; no further extension action required.
SGMO
SANGAMO THERAPEUTICS, INC
other material
negative
materiality 1.00
June 23, 2026, 8:45 AM ET
Sangamo Therapeutics files for Chapter 11 bankruptcy; enters stalking horse asset sales to Lilly and Astellas
- Filed voluntary Chapter 11 petition on June 23, 2026; stock suspended from Nasdaq on May 5, 2026, now trades on OTCQB.
- Entered stalking horse APA with Lilly for $50M to sell technology platforms including STAC-BBB, zinc finger, Modular Integrase, and prion program.
- Entered stalking horse APA with Astellas for $25M upfront plus up to $25M milestones for Fabry disease candidate isaralgagene civaparvovec.
OPIRQ
OFFICE PROPERTIES INCOME TRUST
other material
negative
materiality 0.95
June 23, 2026, 8:06 AM ET
OPI exits Chapter 11, cancels old shares, issues $805M in new secured notes
- Emerged from Chapter 11 on June 17, 2026; old common shares (73.9M) cancelled with no value.
- Issued $420M 10.000% senior secured notes due 2031 and $385M 8.375% notes due 2029.
- ~21.95M new shares issued to noteholders and DIP lenders; noteholders/DIP lenders hold ~67% of new equity.
CSDX
CS DIAGNOSTICS CORP.
other material
negative
materiality 0.90
June 23, 2026, 10:34 AM ET
CS Diagnostics Corp. restates financial statements for 2022-2025 after $499.4M intangible asset error
- Board determined financial statements for FY 2022-2025 cannot be relied upon due to improper recognition of $499.4M intangible asset from Sept 4, 2023 transaction.
- Company engaged Shah Teelani & Associates as new auditor and KBF Advisory as technical accounting advisor to assist with restatement and re-audit.
- Prior audit reports issued by Olayinka Oyebola & Co. also deemed unreliable due to SEC restrictions on that firm.